Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug ...

Enbrel, one of Amgen's established products, faces challenges in the Medicare Part D negotiations, with a 67% discount to list price. While this impacts the drug's profitability, only about 25% of ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...